Genmab reports Rina-S results. Genmab stock falls 1.95 percent

Published on 10/05/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rina-S posted a 45.90 percent response rate among 109 patients. Genmab stock costs EUR 313.75 on October 5, 2026 after EUR 320.00.

Schwarzweiß-Reportage einer Forscherin bei der Analyse von Laborproben im Biotechlabor — Genmab A/S im dokumentarischen Schwarzweiß-Stil zeigt konzentrierte Laborarbeit an Antikörperproben, Aktie mit ISIN DK0010272202, Illustration mit AI erstellt.

Genmab stock (ISIN DK0010272202) was trading at EUR 313.75 at Lang & Schwarz on October 5, 2026 at 11:02 a.m. CEST, down 1.95 percent from the EUR 320.00 prior close. On October 3, 2026, Finanznachrichten reported that Genmab disclosed Phase 2 RAINFOL-01 results for Rina-S in platinum-resistant ovarian cancer.

Rina-S delivers a measurable response

The study covered 109 treated patients and produced a confirmed objective response rate of 45.90 percent, including five complete responses. Median duration of response reached 12.10 months, while median progression-free survival was 9.50 months, according to the October 3 report.

The result gives Genmab a clinical data point as it expands Rina-S across gynecologic oncology. The company is developing the program alongside other late-stage assets, making response durability and progression-free survival important measures for the next development decisions.

Revenue rises as costs increase

For the six months ended June 30, 2026, Genmab generated USD 2,051 million in revenue, up 25.00 percent from USD 1,640 million in the comparable period of 2025. MetaTrader also reported adjusted operating profit of USD 656 million, compared with USD 554 million a year earlier.

Net profit moved in the opposite direction, falling to USD 356 million from USD 531 million. The report attributed the pressure to higher interest expense after acquisition financing, while adjusted operating expenses rose to USD 1,270 million from USD 992 million.

Clinical milestones set the next test

Genmab told Investing.com on September 22, 2026, that Rina-S, EPKINLY and petosemtamab are scheduled for important late-stage readouts in the fourth quarter of 2026 and the first quarter of 2027. Petosemtamab colorectal cancer data are expected at ESMO from October 23 to October 27, 2026.

An exchange-calendar listing shows November 5, 2026 as the date for Genmab's third-quarter report. The calendar creates a defined checkpoint for investors comparing the company's clinical progress with revenue growth and the cost of expanding its pipeline.

Stock trades below prior close

At Lang & Schwarz, Genmab stock was trading at EUR 313.75 on October 5, 2026 at 11:02 a.m. CEST, down 1.95 percent versus the EUR 320.00 prior close dated October 2, 2026. Genmab is listed on Nasdaq Copenhagen under ticker GMAB, with the listing and ISIN confirmed by Global Banking and Finance.

The further course of trading is shown by the continuously updated real-time quote of Genmab stock.